ArticleJournal of clinical microbiology2019
Bringing Antimicrobial Susceptibility Testing for New Drugs into the Clinical Laboratory: Removing Obstacles in Our Fight against Multidrug-Resistant Pathogens.
Article in Journal of clinical microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Why are we doing this alone? A collaborative framework for LDT development and validation.Journal of clinical microbiology · 2026Article
- Antibiotic dose-response curves can measure antibiotic activity againstbioRxiv : the preprint server for biology · 2025Article
- Rapid deprotection and purification of ceftaroline free base from its phosphoramidate prodrug.Journal of medical microbiology · 2025Article
- New Kids on the Block: Estimating Use of Next-generation Gram-negative Antibiotics Across Greater Than 700 Hospitals in the United States.Open forum infectious diseases · 2025Article
- Synthesis, Characterization and Antimicrobial Activity of Trimethylantimony(V) Biscyanoximates, a New Family of Antimicrobials.Molecules (Basel, Switzerland) · 2024Article
- Testing for SARS-CoV-2: lessons learned and current use cases.Clinical microbiology reviews · 2024Review
- Novel antimony-based antimicrobial drug targets membranes of Gram-positive and Gram-negative bacterial pathogens.Microbiology spectrum · 2024Article
- Early appropriate diagnostics and treatment of MDR Gram-negative infections.JAC-antimicrobial resistance · 2022Review
- The Practical Problem With Carbapenem Testing and Reporting Accurate Bacterial Susceptibilities.Frontiers in pharmacology · 2022Review
- Expert Opinion on Verification of Antimicrobial Susceptibility Tests.Journal of clinical microbiology · 2020Article
- New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae.Translational research : the journal of laboratory and clinical medicine · 2020Review
- Hindsight Is 2019-the Year in Clinical Microbiology.Clinical microbiology newsletter · 2020Article
- Verification Is an Integral Part of Antimicrobial Susceptibility Test Quality Assurance.Journal of clinical microbiology · 2020Article
- College of American Pathologists (CAP) Microbiology Committee Perspective: the Need for Verification Studies.Journal of clinical microbiology · 2020Article
- Reply to Humphries and Simner, "Verification Is an Integral Part of Antimicrobial Susceptibility Test Quality Assurance," and Wojewoda et al., "College of American Pathologists (CAP) Microbiology Committee Perspective: the Need for Verification Studies".Journal of clinical microbiology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
There are now several new antibiotics available to treat multidrug-resistant pathogens, and susceptibility testing methods for these drugs are increasingly available at the time of drug approval. However, lack of clarity regarding verification requirements remains a formidable barrier to introducing such testing in clinical laboratories, making these drugs practically unavailable for patient use. We propose a change in the framework for bringing in testing for new antibiotics, focusing on quality control rather than underpowered verification studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.